Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Chadi Saba"'
Autor:
Ali Shamseddine, George Y. Chahine, Chadi Saba, Fadi Nasr, Bassim Kobrossy, W. Moukadem, Joseph Kattan, Dany Abi Gerges, Sarah Abdel Massih, Fadi Farhat
Publikováno v:
Annals of Oncology. 28:iii106
Autor:
Isabelle Ray-Coquard, Sylvie Chabaud, P. Rebattu, Thomas Bachelot, Chadi Saba, Agathe Bajard, Olivier Tredan, Gisèle Chvetzoff, David Pérol, Jean-Yves Blay, Florent Quiblier
Publikováno v:
BMC Cancer
Scopus-Elsevier
BMC Cancer, Vol 11, Iss 1, p 95 (2011)
Scopus-Elsevier
BMC Cancer, Vol 11, Iss 1, p 95 (2011)
Background We aimed to validate prognostic scores for survival in patients undergoing chemotherapy for advanced or metastatic cancer after first-line treatment. Methods We previously described two models with good prognostic value based on a combinat
Autor:
Isabelle, Ray-Coquard, Thomas, Bachelot, Chadi, Saba, Cyrille, Confavreux, Jean-François, Brantus, Fadi, Rustam, Hervé, Ghesquière, Catherine, Sebban, Pierre, Biron, Jean-Paul, Guastalla, Jean-Yves, Blay
Publikováno v:
Bulletin du cancer.
After over 30 years of theorizing, the use of angiogenesis inhibitors as anticancer therapy has finally moved from the realm of research to reality. Normal adult vasculature is generally quiescent in nature, with endothelial cells dividing approximat
Autor:
Thomas Bachelot, C. Poirot, Marie-Jeanne Pierrat, Thibault Chesnel, Frédéric Dubois, Chadi Saba, Mario Campone, V Agrapart, Fabrice Andre
Publikováno v:
Cancer Research. 75:OT1-1
Background: Lucitanib is a potent, oral inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1-3 (FGFR1-3), vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors α/β (PDG
Autor:
Isabelle, Ray-Coquard, Chadi, Saba, Thomas, Bachelot, Pierre, Méeus, Hervé, Mignotte, Rémy, Blondet, Isabelle, Treilleux, Marie, Peix, Jean-Paul, Guastalla
Publikováno v:
Bulletin du cancer. 93(7)
Primary surgical cytoreduction followed by chemotherapy usually is the preferred management of advanced (stage III or IV) ovarian cancer. The presence of residual disease after surgery is one of the most important adverse prognostic factors for survi
Autor:
Fergus Daly, Javier Cortes, Theodora Goulioti, V Agrapart, Fabrice Andre, Martine Piccart-Gebhart, Marc Guitart, Giuseppe Curigliano, Marie Jeanne Pierrat, Chadi Saba, Nicholas C. Turner, Hatem A. Azim, Sherene Loi, Sibylle Loibl, Thibault Chesnel, Ana Catarina Pinto
Publikováno v:
Journal of Clinical Oncology. 32:TPS1134-TPS1134
TPS1134 Background: FGF aberrancy is observed in approximately 25% of breast cancer (BC) patients. Preclinical studies demonstrated that targeting FGFR could lead to antitumor effects. Lucitanib is...
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.